Assessment of Long-Term Alopecia After Adjuvant Taxane Therapy for Early Breast Cancer: A Cross-Sectional Survey

    June 2025 in “ Supportive Care in Cancer ”
    Amy E. Smith, Michelle Harrison, Catriona M. McNeil … Jennifer Lim
    Studysummary This study found that adjuvant docetaxel chemotherapy is linked to higher rates of dissatisfaction and chronic alopecia compared to paclitaxel chemotherapy, suggesting these outcomes should be discussed with patients before using docetaxel regimens.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment, and Prevention Current Oncology · 2024
    2. Redefining The Crown: Approaching Chemotherapy-Induced Alopecia Among Black Patients With Breast Cancer Cancer · 2023
    3. Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors JAMA Dermatology · 2021
    4. Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study ˜The œoncologist · 2018
    5. Permanent Scalp Alopecia Related to Breast Cancer Chemotherapy by Sequential Fluorouracil/Epirubicin/Cyclophosphamide (FEC) and Docetaxel: A Prospective Study of 20 Patients Annals of Oncology · 2012